VIDEO: Intense chemo for fit patients; venetoclax discontinuation results highlighted at ASH
Click Here to Manage Email Alerts
In this video, Eunice Wang, MD discusses acute myeloid leukemia highlights from the ASH Annual Meeting and Exposition.
Studies on intensive chemotherapy for fit patients with acute myeloid leukemia (AML) and research on the discontinuation of venetoclax (Venclexta; AbbVie, Genentech) were among the presentations that Wang, associate professor of oncology, medicine, at Roswell Park Cancer Institute, emphasized.
"There were a number of presentations confirming the benefit and the patient-related outcome improvement, as well as [minimal residual disease] eradication with quizartinib (Vanflyta, Daiichi Sankyo)," Wang said.
"There was just further confirmation that that agent is of benefit," Wang said.
Discussing research that evaluated the discontinuation of venetoclax/azacytidine in certain patients, Wang said that terminating treatment with venetoclax can be associated with overall survival benefit in some patients.
"That represents a potential option maybe, or intriguing possibility for some of our older, unfit patients on long term who are not able to maintain that dual regimen forever," Wang said.
Reference:
- Yilmaz M, et al. Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML. Presented at: ASH Annual Meeting and Exposition, Dec. 9-12, 2023; San Diego.
- Garciaz S, et al. Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study. Presented at: ASH Annual Meeting and Exposition, Dec. 9-12, 2023; San Diego.
Collapse
Healio Interviews
Click Here to Manage Email Alerts